Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $706.06 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 8.6): -1.5; Weak growth.
Regeneron develops and commercializes biotechnology medicines including EYLEA HD and EYLEA (retinal diseases) and Dupixent (dupilumab for inflammatory conditions, co-commercialized with Sanofi). In 2025, EYLEA HD/EYLEA U.S. net product sales were 31% of total revenues, and... Read more
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $706.06 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 8.6): -1.5; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and news soft fda negative. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductEYLEA HD and EYLEA31%10-K Item 1A: 'our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% and 42% of our total revenues, respectively'
- MEDIUMCustomerSanofi collaboration41%10-K Item 1A: 'Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41% and 32% of our total revenues, respectively'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $706.06 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 8.6): -1.5; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $663.53. Score 5.6/10, moderate confidence.
Take-profit target: $789.96 (+11.9% upside). Prior stop was $663.53. Stop-loss: $663.53.
Leverage penalty (D/E 8.6): -1.5; Weak growth; Negative momentum.
Regeneron Pharmaceuticals, Inc. trades at a P/E of 16.5 (forward 13.0). TrendMatrix value score: 6.5/10. Verdict: Sell.
38 analysts cover REGN with a consensus score of 4.1/5. Average price target: $878.
What does Regeneron Pharmaceuticals, Inc. do?Regeneron develops and commercializes biotechnology medicines including EYLEA HD and EYLEA (retinal diseases) and...
Regeneron develops and commercializes biotechnology medicines including EYLEA HD and EYLEA (retinal diseases) and Dupixent (dupilumab for inflammatory conditions, co-commercialized with Sanofi). In 2025, EYLEA HD/EYLEA U.S. net product sales were 31% of total revenues, and Sanofi collaboration revenue (primarily Dupixent profit share) was 41% of total revenues.